arrow
C

Christopher McCabe

queen's university belfast
H指数:43
被引数:6,878

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
2024-08-010
OA
Interventions on gender equity in the workplace: a scoping review
2024-04-052
OAAI
Author Reply
2024-04-011
PRE
We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment

我们需要谈论价值: 在卫生技术评估中阐明规范推理的拟议框架

2023-09-279
OA
OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer
2023-03-011
PRE
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

HER2-positive早期乳腺癌患者6个月与12个月曲妥珠单抗辅助治疗: PERSEPHONE非劣效性RCT

2020-08-0113
OA
OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer
2020-02-150
PRE
Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT
2019-09-0126
OA
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

6个月与12个月曲妥珠单抗辅助治疗HER2-positive早期乳腺癌 (PERSEPHONE): 一项随机3期非劣效性试验的4年无病生存率结果

LANCET
IF88.5
2019-06-01224
OAAI
OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer
2019-02-153
PRE